- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01791868
Efficacy Study of Intravenous Sodium Valproate in Addition to First Line Anti Epileptic Treatment of Generalized Convulsive Status Epilepticus. (VALSE)
Randomized and Multicenter Study Assessing the Efficacy of Intravenous Sodium Valproate in Addition to First Line Anti Epileptic Treatment of Generalized Convulsive Status Epilepticus.
Study Hypothesis Generalized Convulsive Status Epilepticus (GCSE) is a medical emergency associated with an increased morbidity and a prolonged length of hospital stay. Only 50% of patients are discharged from the hospital within the first month after GCSE. Recent Guidelines from Experts highlight the necessity to improve the efficiency of the first line anti-epileptic (AE) therapy.
Intravenous Sodium Valproate (SV) might be an adjuvant AE drug to the recommended first line AEs. Intravenous SV is available, well tolerated and easily injectible but also has pharmacologic properties for reducing the risk of seizures relapses and for being neuroprotective. However, efficacy of intravenous as an adjuvant therapy in GCSE has never been properly assessed.
Primary Purpose The primary purpose is to assess if the association of intravenous Sodium Valproate with the recommended treatment for Generalized Convulsive Status Epilepticus increases to 20 % the number of living patients, discharged from the hospital at day 15.
Study Overview
Status
Intervention / Treatment
Detailed Description
Patient admitted Intensive Care Unit (ICU) for a Generalized Convulsive Status Epilepticus (GCSE) will be randomized if they fulfil the inclusion criteria and after the written informed consent is obtained from the patient's next of kin. In clack of closed relatives, patients could be included according to the French Health Code for Case of medical emergency. In this situation, patient's consent should be then obtained as soon as possible According to randomization arm, patients will be treated either by intravenous sodium valproate (30 mg/kg during 15 min then 1 mg/kg/h during 12 h) or intravenous placebo. All included patients will benefit from first-line anti epileptic drugs and symptomatic medical care, in agreement with the Experts recommendation (RFE 2009).
From day-1 to day-15, level consciousness(Glasgow Coma Scale, Richmond Agitation Sedation Scale), delirium (Confusion Assessment Method For Intensive Care Unit), reoccurrence of seizure, vital signs, organ dysfunction (Simplified Acute Physiology Score II, Sequential Organ Failure) will be daily assessed.
At day 2, the preventive oral anti-epileptic drug will be prescribed by a neurologist, blinded from randomization.
At Day 15 and Day 30, neurological status, cognitive functions (Mini Mental State Examination, Frontal Assessment Battery, Glasgow Outcome Scale), and quality of life (SF36) will be assessed by a neurologist, also not aware of the randomization.
The number of patients alive and discharged from Hospital day 15 15th day will assessed.
300 patients with GCSE will be randomized, 150 in each arm, in 16 ICUs and over a period of 3 years.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Haute DE Seine
-
Garche, Haute DE Seine, France, 92380
- Hôpital Raymond Poincaré
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient older than 18.
Admitted in a participating ICU for generalized convulsive status epilepticus (GCSE) i.e. with persistent or repeated generalized seizures without regaining consciousness over a period of five minutes. provided that the duration of the treatment prior antiepileptic does not exceed:
- Six hours if GCSE is already controlled at the time of inclusion (= disappearance seizures regardless of the state of consciousness)
- Twenty-four hours if GCSE persisted or is recurrent.
- Written informed consent collected from close relation or a family member of the patient. Otherwise, inclusion according to French Health Code in case of medical emergency. In this case, the written informed consent of patient has to be collected as soon as possible then. in absence of a close of patient, the patient may be still included. the consent of the prosecution will be collected
Exclusion Criteria:
- Other type of status epilepticus (including atypical form) occured before the onset of anti epileptic.
- Female patient of childbearing age ≥ 18 ans et < 50 ans
- Patient prior treated by depakine in emergency for the GCSE
- The length of stay in hospital expected before the occurrence of GCSE > 15 days.
- Expected Length of stay in ICU <12h .
- Hypoxic-ischemic encephalopathy.
- Pregnant women, eclampsia checked by a systematic pregnancy test.
- Pre-existing chronic or acute hepatitis, or Cirrhosis B or C.
- Family history of acute hepatitis, especially drug-related hepatitis
- Other sodium valproate Contraindications : Hypersensitivity to sodium valproate or derivatives, acute or chronic hepatitis; personal or family history of severe hepatitis, in particular drug; hepatic porphyria, mefloquine or hypericum taking.
- life expectancy expected ≤ 3 months.
- Patients already included in another clinical trial on GCSE.
- Non affiliation to a social health care.
- Patients under tutelage.
- Patient has already been included in this protocol and who completed the clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intravenous sodium valproate
Intravenous sodium valproate: 30 mg/kg during 15 min then 1 mg/kg/h during 12 h |
According to randomization arm, patients will be treated either by intravenous sodium valproate (30 mg/kg during 15 min then 1 mg/kg/h during 12 h) or intravenous placebo.
All included patients will benefit from first-line anti epileptic drugs and symptomatic medical care, in agreement with the French Experts Recommendation 2009(RFE 2009).
Other Names:
|
Placebo Comparator: Intravenous Placebo
Intravenous Placebo: NaCl 0,9 % during 15 min at first then during 12 h. |
According to randomization arm, patients will be treated either by intravenous sodium valproate (30 mg/kg during 15 min then 1 mg/kg/h during 12 h) or intravenous placebo.
All included patients will benefit from first-line anti epileptic drugs and symptomatic medical care, in agreement with the French Experts Recommendation 2009(RFE 2009).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients in ICU for a GCSE discharged alive from the hospital at Day 15.
Time Frame: 15 days
|
Increasing by 20 % the number of patients admitted in ICU for a GCSE who will be discharged alive from the hospital at Day 15.
|
15 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of refractory status epilepticus
Time Frame: 3 months
|
To determine if intravenous SV as an adjuvant anti-epileptic drug, and irrespectively of the cause of GCSE, decreases as frequency of refractory status epilepticus at 3 months without increase in rate of side effects.
|
3 months
|
Morbidity related to ICU stay
Time Frame: 3 months
|
To determine if intravenous SV as an adjuvant anti-epileptic drug, and irrespectively of the cause of GCSE, decreases as morbidity related to ICU stay at 3 months without increase in rate of side effects.
|
3 months
|
Cognitive dysfunction
Time Frame: 3 months
|
To determine if intravenous SV as an adjuvant anti-epileptic drug, and irrespectively of the cause of GCSE, decreases as cognitive dysfunction at 3 months without increase in rate of side effects.
|
3 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Hervé OUTIN, MD, Service de Réanimation Médico Chirurgicale, Hôpital Poissy Saint-Germain en Laye
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neurologic Manifestations
- Seizures
- Status Epilepticus
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Enzyme Inhibitors
- Tranquilizing Agents
- Psychotropic Drugs
- GABA Agents
- Anticonvulsants
- Antimanic Agents
- Valproic Acid
Other Study ID Numbers
- P100148
- 2011-006340-75 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intensive Care Unit
-
University of MelbourneEnrolling by invitationICU Acquired Weakness | Intensive Care Unit Syndrome | Intensive Care Unit Acquired Weakness | Post Intensive Care Unit Syndrome | Post Intensive Care SyndromeAustralia
-
Seoul National University HospitalMinistry of Food and Drug Safety, KoreaCompletedPostoperative Care | Intensive Care UnitKorea, Republic of
-
Centre Hospitalier Régional d'OrléansRecruiting
-
Nantes University HospitalRecruiting
-
Mayo ClinicCompletedPalliative Care | Intensive Care Unit | HospiceUnited States
-
First People's Hospital of ChenzhouRecruiting
-
Hospira, now a wholly owned subsidiary of PfizerCompleted
-
Hospital Israelita Albert EinsteinActive, not recruitingCritical Care | Intensive Care UnitBrazil
-
Hospices Civils de LyonCompletedPediatric Intensive Care UnitFrance, Belgium, Lebanon, Switzerland
-
Taipei Veterans General Hospital, TaiwanCompletedIntensive Care Unit PatientsTaiwan
Clinical Trials on Intravenous Sodium Valproate
-
University of BirminghamActive, not recruitingWolfram SyndromeFrance, United Kingdom, Poland, Spain
-
Sheba Medical CenterTel Aviv UniversityCompletedVerifying the Correct Position of Intravenous CathetersIsrael
-
TularikUnknownHepatocellular CarcinomaUnited States, China
-
TularikTerminatedNon-Hodgkin's LymphomaUnited States
-
TularikUnknownOvarian NeoplasmsUnited States
-
TularikSuspendedGastric Cancer | Esophageal NeoplasmsUnited States
-
Xijing HospitalUnknownTraumatic Brain InjuryChina
-
The Western Pennsylvania HospitalWest Penn Allegheny Health SystemWithdrawnContrast Induced NephropathyUnited States
-
All India Institute of Medical Sciences, New DelhiUnknownChronic Lymphocytic LeukemiaIndia
-
Guy's and St Thomas' NHS Foundation TrustActive, not recruiting